FDA, COVID-19 and vaccine
Digest more
No, this is not true. Vaccines undergo rigorous safety testing and are continuously monitored for adverse events.
The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by Novavax,
The most commonly reported adverse events with the AZD1222 COVID-19 vaccine are headache and fatigue, a large-scale active surveillance study from the United Kingdom shows.
U.S. regulators will no longer approve COVID booster shots for healthy adults and children without new studies, adding a costly requirement for drugmakers, though they will still be available for millions of high-risk Americans.
1d
Live Science on MSN2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayedLate-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.